HUP0004802A2 - Nikotintartalmú kompozíciók és eljárás előállításukra - Google Patents

Nikotintartalmú kompozíciók és eljárás előállításukra

Info

Publication number
HUP0004802A2
HUP0004802A2 HU0004802A HUP0004802A HUP0004802A2 HU P0004802 A2 HUP0004802 A2 HU P0004802A2 HU 0004802 A HU0004802 A HU 0004802A HU P0004802 A HUP0004802 A HU P0004802A HU P0004802 A2 HUP0004802 A2 HU P0004802A2
Authority
HU
Hungary
Prior art keywords
nicotine
formulation
methods
liquid crystal
nicotine compositions
Prior art date
Application number
HU0004802A
Other languages
English (en)
Inventor
Sven Börje Andersson
Stefan Jonn
Tomas Landh
Original Assignee
Pharmacia And Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia And Upjohn Ab filed Critical Pharmacia And Upjohn Ab
Publication of HUP0004802A2 publication Critical patent/HUP0004802A2/hu
Publication of HUP0004802A3 publication Critical patent/HUP0004802A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgyát nikotint tartalmazófolyadékkristályos poláros lipid kompozíciók és az azokból képzettkolloid diszperziók és ezek prekurzorai vagy származékai képezik,amelyek a testfolyadékokkal érintkezésbe kerülve és/vagy atesthőmérséklet hatására folyadékkristállyá vagy folyadékkristályoskeverékké alakulnak és szabályozott nikotin-felszabadulást biztosítómátrixként működnek, amelyek például a dohányzást megszüntető és/vagya dohányzást helyettesítő terápiában használhatóak. Ó
HU0004802A 1997-09-25 1998-09-15 Nicotine compositions and methods of formulation thereof HUP0004802A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703458A SE9703458D0 (sv) 1997-09-25 1997-09-25 Nicotine compositions and methods of formulation thereof
PCT/SE1998/001632 WO1999015171A1 (en) 1997-09-25 1998-09-15 Nicotine compositions and methods of formulation thereof

Publications (2)

Publication Number Publication Date
HUP0004802A2 true HUP0004802A2 (hu) 2001-05-28
HUP0004802A3 HUP0004802A3 (en) 2001-12-28

Family

ID=20408364

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004802A HUP0004802A3 (en) 1997-09-25 1998-09-15 Nicotine compositions and methods of formulation thereof

Country Status (22)

Country Link
EP (1) EP1023069B1 (hu)
JP (1) JP2001517624A (hu)
KR (1) KR20010024305A (hu)
CN (1) CN1123343C (hu)
AT (1) ATE253362T1 (hu)
AU (1) AU733619B2 (hu)
BR (1) BR9815395A (hu)
CA (1) CA2304042A1 (hu)
DE (1) DE69819548T2 (hu)
DK (1) DK1023069T3 (hu)
EE (1) EE200000154A (hu)
ES (1) ES2210817T3 (hu)
FI (1) FI20000692A (hu)
HU (1) HUP0004802A3 (hu)
MX (1) MXPA00002955A (hu)
NO (1) NO20001540L (hu)
NZ (1) NZ503408A (hu)
PT (1) PT1023069E (hu)
RU (1) RU2201747C2 (hu)
SE (1) SE9703458D0 (hu)
WO (1) WO1999015171A1 (hu)
ZA (1) ZA988794B (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US6799576B2 (en) 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
AT409219B (de) * 1999-08-13 2002-06-25 Red Bull Gmbh Verwendung von nikotin zum herstellen von arzneimitteln
KR100381622B1 (ko) * 2000-08-30 2003-04-26 디디에스텍주식회사 자극성을 줄인 염기성 약물의 구강 투여 조성물
DE10057769A1 (de) * 2000-11-22 2002-05-23 Beiersdorf Ag Haarpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
AU2003209750A1 (en) * 2002-03-30 2003-10-13 Gunther Beisel Preparation containing fatty acid, used for reducing appetite, satiating, and/or reducing weight
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings
KR100443722B1 (ko) * 2002-09-26 2004-08-09 이용원 니코틴을 함유한 하드츄잉캔디 및 그의 제조방법
DE60313216T2 (de) 2002-12-20 2008-01-03 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
US9498454B2 (en) * 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US8992974B2 (en) * 2003-02-24 2015-03-31 Pharmaceuticals Productions, Inc. Transmucosal drug delivery system
GB0322033D0 (en) * 2003-09-19 2003-10-22 Camurus Ab Composition
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
CN104397869B (zh) 2003-11-07 2016-06-08 美国无烟烟草有限责任公司 烟草组合物
US7125954B2 (en) 2005-01-27 2006-10-24 General Electric Company Method for producing polyether polymers
US20080219935A1 (en) * 2005-07-08 2008-09-11 Sang-Hoon Kwak Phase Transitive Breath Care Products
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
WO2007118653A2 (de) * 2006-04-11 2007-10-25 Koko Kosmetikvertrieb Gmbh & Co. Kg Nanopartikel, enthaltend nicotin und/oder cotinin, dispersionen und die verwendung derselben
US20080287507A1 (en) * 2007-05-16 2008-11-20 John Hedenstrom Nicotine containing toiletry waters
GB2469792A (en) * 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
GB2476471A (en) * 2009-12-22 2011-06-29 Norwich Pharma Technologies Ltd Cotinine formulation for the treatment of obesity
US8846725B2 (en) * 2011-01-24 2014-09-30 Quadex Pharmaceuticals, Llc Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
CN102552405B (zh) * 2012-03-21 2013-10-16 张伟 一种肛周术后麻醉镇痛的药物组合物的制备方法
CN103040741B (zh) * 2012-12-11 2014-11-05 中山大学 溶致液晶的前体混悬液及其制备方法
US20160015703A1 (en) * 2013-03-07 2016-01-21 Danmarks Tekniske Universitet Nano- microdelivery systems for oromucosal delivery of an active ingredient
KR20230013165A (ko) * 2013-05-06 2023-01-26 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 염 제제 및 그 방법
WO2015090337A1 (en) * 2013-12-20 2015-06-25 Fertin Pharma A/S Nicotine powder composition
CN105828819A (zh) * 2014-04-08 2016-08-03 桑萨（巴巴多斯）公司 烟碱制剂及其制备方法
GB201414919D0 (en) * 2014-08-21 2014-10-08 Corbitt Terence Simon Formulations for transmucosal delivery
CN108323791B (zh) * 2018-01-03 2021-02-12 云南中烟工业有限责任公司 一种尼古丁-氧化锌复合物、其制备方法及包含其的烟草制品
CA3096580C (en) * 2018-04-16 2023-05-23 Poviva Corp. Compositions infused with nicotine compounds and methods of use thereof
CN109125251B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 一种包载蛋白类药物的温敏性液晶凝胶制剂及其制备方法
KR102186704B1 (ko) 2019-02-18 2020-12-04 (주)아이엠디팜 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물
LU101511B1 (en) * 2019-12-02 2021-06-04 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a parenteral administration and a process for the preparation of an injectable substance
LU101520B1 (en) * 2019-12-02 2021-06-07 Herrera Arturo Solis (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication
NL2031331B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of a short-acting psychedelic compound
NL2031332B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of psychoactive compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5371109A (en) * 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
IL86170A (en) * 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US4908213A (en) * 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
GB2230439A (en) * 1989-04-20 1990-10-24 Alec Stanley Walter Shaw Nicotine lozenges
ES2133391T3 (es) * 1991-10-04 1999-09-16 Gs Dev Ab Particulas, metodo para preparar dichas particulas y usos de las mismas.
WO1997013528A1 (en) * 1995-10-12 1997-04-17 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface

Also Published As

Publication number Publication date
EP1023069B1 (en) 2003-11-05
FI20000692A (fi) 2000-03-24
ES2210817T3 (es) 2004-07-01
CN1123343C (zh) 2003-10-08
KR20010024305A (ko) 2001-03-26
WO1999015171A1 (en) 1999-04-01
EE200000154A (et) 2001-02-15
BR9815395A (pt) 2000-11-14
ATE253362T1 (de) 2003-11-15
CN1278174A (zh) 2000-12-27
NO20001540L (no) 2000-05-25
NO20001540D0 (no) 2000-03-24
ZA988794B (en) 1999-04-01
DK1023069T3 (da) 2004-03-08
EP1023069A1 (en) 2000-08-02
SE9703458D0 (sv) 1997-09-25
RU2201747C2 (ru) 2003-04-10
AU733619B2 (en) 2001-05-17
HUP0004802A3 (en) 2001-12-28
NZ503408A (en) 2004-12-24
JP2001517624A (ja) 2001-10-09
DE69819548D1 (de) 2003-12-11
MXPA00002955A (es) 2002-04-24
AU9287298A (en) 1999-04-12
CA2304042A1 (en) 1999-04-01
PT1023069E (pt) 2004-02-27
DE69819548T2 (de) 2004-08-12

Similar Documents

Publication Publication Date Title
HUP0004802A2 (hu) Nikotintartalmú kompozíciók és eljárás előállításukra
SE9604793L (sv) Nya Kristallmodifikationer
HUP0001818A2 (hu) A szem első kamrájában alkalmazható szabályzott felszabadulású gyógyszerhatóanyagok
DK0699103T3 (da) Overflademodificerede, biokompatible membraner
GEP20032954B (en) Heterocyclic Inhibitors of P38
ES2104157T3 (es) Emplasto con sustancias activas, para sustancias activas de bajo punto de fusion y/o volatiles.
DE69400799T2 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
BR0104391A (pt) Produto céreo para cabelos, com cera, óleos não-voláteis e substâncias hidrofóbicas voláteis
CY1108320T1 (el) Συνεργια προσδεματος apo-2 και αντισωματος anti-her-2
NO971965D0 (no) Farmasöytisk preparat inneholdende en smeltbar bærer og fremgangsmåte for fremstilling derav
DE69811378D1 (de) Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
NZ304291A (en) Trisubstituted phenyl derivatives, preparation and pharmaceutical compositions thereof
DK100487D0 (da) Hidtil ukendte carbonsyrederivater, fremgangsmaade til deres fremstilling, deres anvendelse samt laegemidler indeholdende disse forbindelser
NZ240481A (en) Aminosulphonyl urea derivatives and pharmaceutical compositions
ES2183814T3 (es) Composicion farmaceutica que contiene il-6 y su uso para el tratamiento del trastorno trombohemorragico de consumo.
HUP0301056A2 (en) Novel needle for medical device and device comprising same
BR9814496A (pt) Composto, processos para a preparação de cristais de sementes da modificação termodinamicamente estável i de ramatroban, para a preparação de uma forma termodinamicamente estável de ramatroban, medicamento, e, uso de uma modificação termodinamicamente estável de ramatroban
ATE186214T1 (de) Verwendung von rosmanolderivaten zur herstellung von antiradikalischen und/oder antilipoperoxidativen und/oder hepatotropen arzneistoffen
AU665397B2 (en) Fungicidal compositions
BR0115332A (pt) Leite estéril, estável e método para a sua produção
FI952855A0 (fi) Uudet triatsolokinatsoliinit, niiden valmistus ja käyttö
Diamond Diagnosis of migraine
ATE203671T1 (de) Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen
NO307204B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter ved behandling av stråleskader

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees